PDCD1 and hepatoid adenocarcinoma: This study aims to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1) blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS).